Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carboplatin in pediatric malignancies

P S Gaynon1

  • 1Department of Pediatrics, University of Wisconsin, Madison.

Seminars in Oncology
|October 1, 1994
PubMed
Summary

Carboplatin offers a similar cancer treatment spectrum to cisplatin but with reduced severe side effects like kidney and ear damage. Its main toxicity is myelosuppression, manageable with rescue therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Leukemia·2014
Same author

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.

Leukemia·2014
Same author

The principle and practice of reinduction therapy (in ALL): repetita iuvant!

Klinische Padiatrie·2013
Same author

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.

Leukemia·2009
Same author

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Leukemia·2008
Same author

High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative.

Leukemia·2005

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cisplatin is a widely used chemotherapy agent for pediatric cancers.
  • Cisplatin's utility is limited by severe ototoxicity, nephrotoxicity, and emetogenicity.
  • Carboplatin, a cisplatin analogue, presents an alternative with a different toxicity profile.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of carboplatin in cancer treatment.
  • To compare carboplatin's side effect profile with that of cisplatin.
  • To explore carboplatin's potential in pediatric and adult malignancies, including those resistant to cisplatin.

Main Methods:

  • Clinical trials investigating carboplatin in various cancer types.
  • Dose-finding studies correlating drug dosage and glomerular filtration rate with myelosuppression.
  • Combination therapy studies involving carboplatin with other agents like ifosfamide.

Main Results:

  • Carboplatin demonstrates a comparable activity spectrum to cisplatin.
  • The primary toxicity of carboplatin is myelosuppression, which is predictable and manageable.
  • Carboplatin shows activity in adult acute myeloblastic leukemia, a setting where cisplatin is less effective.
  • Carboplatin is being explored in children with brain tumors and acute leukemia, often with supportive care.

Conclusions:

  • Carboplatin is a viable alternative to cisplatin, particularly for pediatric cancers, due to its improved toxicity profile.
  • Myelosuppression is the dose-limiting toxicity of carboplatin, but it can be effectively managed.
  • Carboplatin's reduced nephrotoxicity and ototoxicity make it suitable for combination therapies and in susceptible patient populations.

Related Experiment Videos